JANX - CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
2024-04-25 18:33:59 ET
Summary
- CytomX Therapeutics is a biotech company developing anticancer therapeutics using a technology that activates an immune response within the tumor microenvironment.
- Their main pipeline candidate, CX-904, is a bispecific "probody" targeting EGFR and CD3, being assessed in a phase 1 trial.
- The company has a strategic collaboration with Amgen for CX-904 and with Astellas for CX-2051, an antibody-drug conjugate targeting EpCAM.
Topline Summary
CytomX Therapeutics ( CTMX ) is a biotech company specializing in the development of anticancer therapeutics, hoping to leverage a technology that allows for specific activation of an immune response within the tumor microenvironment. In one sense, they seem like a parallel, less-lucky version of Janux Therapeutics ( JANX ), a phase 1 biotech leveraging an early data readout into a multi-billion market cap....
CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town